MOR News and Press, MorphoSys AG From 06/13/22

Gainers: MorphoSys  (MOR) +20%. NGM Biopharmaceuticals (NGM) +14%. National Vision Holdings (EYE) +10%. Editas Medicine (EDIT) +10%. Hyzon Motors  (HYZN) +5%. Losers: Outset Medical (OM) -22%. Redbox Entertainment  (RDBXW) -14%. Xperi Holding Corporation (XPER) -7%. C...

New translational data suggests potential disease-modifying effects following treatment with pelabresib of both first-line and ruxolitinib-relapsed/refractory patients A comparative model suggests an improvement in SVR35 and TSS50 in JAK inhibitor-naïve myelofibrosis pati...

NAT is bullish on spot tanker rates because of Russia's involvement in armed conflict with Ukraine, and most of its tankers are in the spot market. However, Suezmax tanker rates have dropped since their spike. Oil demand fundamentals have softened and high oil prices are dampening...

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / May 18, 2022 / MorphoSys AG (FSE:MOR); (NASDAQ:MOR) announced today that its shareholders approved all resolutions proposed by the Company´s Management and Supervisory Boards at the Company´s virtual Annual General Meeting which took place o...

Efficacy and safety data from the ongoing Phase 2 MANIFEST study of pelabresib in myelofibrosis will be featured during an oral presentation at the EHA 2022 Hybrid Congress Translational research that suggests pelabresib’s potential disease modifying effect in patients ...

MorphoSys AG (MOR) Q1 2022 Earnings Conference Call May 05, 2022, 08:00 AM ET Company Participants Julia Neugebauer - IR Jean-Paul Kress - CEO Sung Lee - CFO Malte Peters - Chief Research & Development Officer Joe Horvat - U.S. General Manager Conference Call Participants James Quigley - ...

Image source: The Motley Fool. MorphoSys AG (NASDAQ: MOR) Q1 2022 Earnings Call May 05, 2022 , 8:00 a.m. ET Operator Continue reading For further details see: MorphoSys AG (MOR) Q1 2022 Earnings Call Transcript

MorphoSys press release (NASDAQ:MOR): Q1 GAAP EPS of -€3.59. Revenue of €41.5M. Shares -0.37% AH. For further details see: MorphoSys GAAP EPS of -€3.59, revenue of €41.5M

MorphoSys stock has taken a huge hit since its Constellation buyout. The company has staked an entire existing revenue stream for a development stage asset. The market hasn't taken this kindly. For further details see: MorphoSys May Not Recover From Adventurous Constella...

– Monjuvi ® U.S. net product sales of US$ 18.7 million (€ 16.6 million) for the first quarter 2022, a 21% year-over-year growth – NCCN ® updated the designation of Monjuvi to preferred regimen in its Clinical Practice Guidelines in Oncolo...